Physician profile
Danny Vandan
NPI 1215363643
$2,884.51
in general payments reported to CMS, 2019-2025
13 companies · $757 in 2025
The $757 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.24 · 2020: $17.05 · 2021: $400 · 2022: $602 · 2023: $519 · 2024: $575 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,850.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $667.21 | 2020-2025 | Precision7, Precision 1, Dailies |
| Coopervision INC. | $521.00 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Synergeyes Contact Lens |
| Biotissue Holdings INC. | $372.25 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $345.87 | 2022-2025 | Xiidra, Miebo, Infuse |
| Johnson & Johnson Vision Care, INC. | $234.91 | 2023-2025 | Acuvue |
| Abbvie INC. | $180.47 | 2022-2023 | |
| Horizon Therapeutics Plc | $146.77 | 2023 | Tepezza |
| Topcon Healthcare, INC. | $138.23 | 2025 | |
| Allergan, INC. | $123.79 | 2022 | |
| Thea Pharma INC. | $67.27 | 2022-2025 | Iyuzeh |
| Amgen INC. | $47.89 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $24.33 | 2024 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Vandan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.